There is no evidence of an increased risk of suicidal or self-injurious thoughts and actions with GLP-1 agonists used to treat diabetes amd obesity, according to the EU medicines regulator.
Along with other world regulators – including the FDA in the US, the UK MHRA and Health Canada – the EMA started its review of the safety of the fast-growing class last year after reports of suicidal thoughts or self-injury in a small number of patients taking them.
